Arvinas appoints new president, CEO
This article was originally published in Scrip
Executive Summary
New Haven, Connecticut-based Arvinas, a biotechnology company creating a new class of oncology drugs based on protein degradation, has appointed Dr Manuel Litchman president and CEO of the company. Dr Litchman was most recently senior vice-president and global program head at Novartis Pharmaceuticals.